by microbiome | Jun 12, 2023 | Highlights, Microbiomes & cancer, Vaiomer original work
doi: 10.1158/2159-8290.CD-21-0999 Numerous metagenomics-based studies have associated gut microbiota dysbiosis with the progression and resistance to immunotherapy of intestinal and non-intestinal cancers. It remains unclear whether the dysbiosis is causing the...
by microbiome | Apr 27, 2023 | Highlights, News
Physiogenex and Vaiomer Launch the TRANSBIOTIC project: A New Collaborative Research Project on mouse models transplanted with Human Microbiome Physiogenex, a leading preclinical contract research organization specialized in metabolic diseases and complications, and...
by microbiome | Apr 24, 2023 | Highlights, Microbiomes & Metabolism, Vaiomer original work
doi: 10.1371/journal.pone.0260765 Prebiotic, probiotic and symbiotic treatments affect intestinal and adipose tissue microbiomes, as well as gut and liver metabolites This article by Yde et al., explored the changes in the microbiota composition and metabolite levels...
by microbiome | Apr 24, 2023 | Highlights, Microbiomes & Metabolism, Vaiomer original work
DOI: 10.1503/jpn.200159 Response to antidepressant is associated with blood microbiome and metabolome of patients with major depressive episodes (MDE) In this article, Ciocan and colleagues explored the blood microbiome and metabolome in patients with major depressive...
by microbiome | Apr 6, 2023 | Highlights, Microbiomes & Metabolism, Vaiomer original work
DOI: 10.1016/j.jhepr.2021.100299 Changes in the liver microbiome as a risk factor for the development of NAFLD in obese individuals In this paper, Suppli et al., study the microbiome in liver biopsies and blood from healthy lean and obese patients: → Liver...
